Chiesi and Protalix Secure EU Approval for Extended Dosing Regimen of Fabry Disease Therapy
Event summary
- European Commission approved a 2mg/kg every-4-weeks dosing regimen for Elfabrio® (pegunigalsidase alfa) in adults with stable Fabry disease.
- Approval follows positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP).
- Protalix BioTherapeutics is entitled to a $25 million regulatory milestone payment from Chiesi.
- The new dosing regimen aims to reduce treatment burden for patients and healthcare systems.
- Approval does not affect the FDA-approved dosing regimen in the US, which remains 1mg/kg every 2 weeks.
The big picture
The approval of the extended dosing regimen for Elfabrio® reflects a strategic push to enhance treatment flexibility for Fabry disease patients, aligning with broader industry trends toward patient-centric care. This move could set a precedent for other enzyme replacement therapies, potentially influencing regulatory and commercial strategies in the rare disease space. The $25 million milestone payment underscores the financial stakes in optimizing treatment delivery for chronic conditions.
What we're watching
- Market Expansion
- How Chiesi and Protalix will leverage this approval to broaden access across the EU.
- Regulatory Dynamics
- Whether the FDA will follow with a similar approval for the extended dosing regimen in the US.
- Commercial Strategy
- The pace at which Chiesi can integrate this new dosing option into existing treatment protocols.
Related topics